MediPost Completes Phase 3 Trial of Cartistem in Japan... Results to Be Announced in Q2
All Patient Data Secured Following Last Patient Out (LPO) in November Last Year
MediPost has completed the phase 3 clinical trial in Japan for Cartistem, its allogeneic umbilical cord blood-derived mesenchymal stem cell therapy. In November of last year, the company completed the final patient visit, securing all patient data, and has now entered the stage of preparing the clinical trial results report. MediPost plans to release the results in the second quarter of this year.
According to MediPost on March 3, this phase 3 clinical trial in Japan was conducted at 13 institutions across the country, targeting 130 patients with moderate to severe knee osteoarthritis. The trial was designed as a randomized, observer-blinded study with hyaluronic acid injection as the control group. Safety and efficacy were evaluated through a 52-week follow-up observation.
This phase 3 trial simultaneously set two primary efficacy endpoints. Along with patient-reported outcomes that assess pain and functional improvement, structural indicators were included to directly confirm cartilage regeneration through secondary verification with arthroscopy. This is a differentiated structure compared to typical osteoarthritis phase 3 trials, which are generally designed around subjective indicators such as pain improvement.
The company aims to receive the results report within the first half of the year and is targeting to submit an application for product approval in Japan in the second half. The target for obtaining approval is by the end of 2027.
Previously, in December of last year, MediPost signed an exclusive sales license agreement in Japan with Teikoku Pharma. Under the agreement, MediPost is expected to receive a signing payment of KRW 11.8 billion and regulatory milestone payments totaling KRW 14.8 billion. The company also anticipates future revenue from sales milestones and the supply of raw materials and finished products.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
In the United States, MediPost recently obtained approval for the clinical trial plan for phase 3. The company plans to accelerate development with the goal of enrolling the first patient in the first quarter of this year. The target for obtaining approval in the United States is 2031.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.